ACI's Premiere Conference on Life Sciences Antitrust
* Pay-for-Delay Lawsuits *
* Price Fixing Investigations *
* M&A Scrutiny in the U.S. and Abroad *
* New Antitrust Enforcement Policies *
Now more than ever, life sciences companies must remain abreast of the emerging enforcement trends as well as the government’s antitrust analysis for evaluating anticompetitive behavior.
As we proceed through 2021, the spotlight on antitrust activity in the life sciences industry shines brighter than ever. For several years, state and federal antitrust enforcers in the U.S. and even international antitrust and competition authorities have been watching the life sciences industry closely for anticompetitive activity. The Biden Administration is now forming its new competition policy and there is pending antitrust legislation which will unquestionably affect the life sciences industries. At the same time, the U.S. DOJ has just confirmed that they are developing new policies to prevent patents from being used as tools for anticompetitive practices, a recent series of criminal antitrust investigations have been brought by federal and state authorities alleging generic price fixing collusion, and a novel multinational task force has just been put in place to examine the anticompetitive impact of life sciences M+A activity. All of these new changes are raising life sciences antitrust concerns to an all-time high, and could significantly increase the volume of litigation for IP and antitrust trial lawyers and their clients.
Don’t miss your chance to attend the only event on the market where you can hear from antitrust enforcers, leading in-house counsel, and law firm attorneys on how to successfully tackle the most complex antitrust challenges currently facing biopharmaceutical manufacturers.
Leading antitrust counsel will participate in discussions and provide analysis on:
- Current FTC and European Competition Authority Priorities in Life Sciences Antitrust Enforcement
- The Latest Legislation and Competition Policy Being Contemplated by the Biden Administration
- What the Global Life Sciences Industry Needs to Know About The “Multilateral Pharmaceutical Merger Task Force”
- Recent Criminal Generic Price Fixing Cases and How They May Change the Outlook for Competition in the Industry
- Future Forecasts for Reverse-Payment Settlement Litigation, Patent Thicketing, and Restrictive Distribution Agreements
- The Implications of Recent Court Decisions and Enforcement Activity Related to Product Hopping, Sham Petitioning, Product Bundling, and Loyalty Rebating
View the Full Agenda & List of Distinguished Speakers and Register Today!
pharmaphorum Readers SAVE 10%! Mention code: D10-760-760DX02 when registering.
CLE Accreditation Available.